

RECEIVED
CENTRAL FAX CENTER



AUG 11 2006

GlaxoSmithKline

FAX

To Attn: Examiner Deepak Rao , Group 1624
.....
Company USPTO
.....
Fax (571) 273-8300
.....
From Patty Wilson
.....
Tel 1-919-483-1007; Facsimile: 1-919-483-7977
.....
E-mail patricia.t.wilson@gsk.com
.....
Date August 11, 2006 Pages including cover 11
.....
Application of: Andrews III et al.
Subject U.S. Serial No.: 10/070,084
Attorney Docket No. PU3517USw
.....

GlaxoSmithKline
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709

Tel: 919 483 2100
www.gsk.com

Attached: Supplemental IDS and 1449
(1) reference

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

Atty. Docket No. PU3517USw

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED
CENTRAL FAX CENTER

IN RE: Application of Clarence Webster ANDREWS III et al.

AUG 11 2006

Serial No.: 10/070,084

Art Unit: 1624

Filing Date: August 31, 2000

Examiner: Rao, Deepak

For: *Benzophenones as Inhibitors of Reverse Transcriptase*

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the reference(s) are enclosed.
- [] Copies of the references were submitted in parent application Serial No. _____.
 (37 CFR 1.98(d))
- [] A copy of the International Search Report which issued on International Application No. _____ is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. [] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
- OR
- [] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. [X] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
- (1) a final action under § 1.113 or
 - (2) a notice of allowance under § 1.311,
- whichever occurs first.

I hereby certify that this correspondence is being facsimile transmitted to (571) 272-8300 on

August 11, 2006
Patty Wilson
 Patty Wilson

Atty. Docket No. PU3517USw

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee.


In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

Please charge any required fees to Deposit Account No.07-1392.

A duplicate copy of this paper is attached.

Respectfully Submitted,



Kimberly H. Parker
Attorney of Record
Registration No. 47,843

Date: August 11, 2006
Customer No. 23347
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398
Telephone: (919) 483-8406
Facsimile: (919) 483-7988

Page 1 of 1